✦ LIBER ✦

Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, Reduces High Plasma Lp(a) Concentration: Pooled Analysis of 352 Patients from Phase 2

✍ Scribed by Gaudet, Daniel; Kereiakes, Dean; McKenney, James; Roth, Eli; Hanotin, Corinne; Gipe, Dan; Du, Yunling; Ferrand, Anne-Catherine; Ginsberg, Henry; Stein, Evan

Book ID: 123076504
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 58 KB
Volume: 7
Category: Article
ISSN: 1933-2874
DOI: 10.1016/j.jacl.2013.03.091

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, Safety and Tolerability of Ali

Efficacy, Safety and Tolerability of Alirocumab 150 mg Q2W, a Fully Human PCSK9 Monoclonal Antibody: A Pooled Analysis of 352 Patients from Phase 2

✍ Koren, Michael Joseph; Stein, Evan; Roth, Eli; McKenney, James; Gipe, Dan; Hanot 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 54 KB

Efficacy and Safety of AMG 145, a Fully

Efficacy and Safety of AMG 145, a Fully Human Monoclonal Antibody to PCSK9: Data from Four Phase 2 Studies in Over 1200 Patients

✍ Raal, Frederick; Giugliano, Robert; Koren, Michael J.; Sullivan, David; Roth, El 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 43 KB

Effect of Alirocumab, a Monoclonal Propr

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

✍ Gaudet, Daniel; Kereiakes, Dean J.; McKenney, James M.; Roth, Eli M.; Hanotin, C 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 509 KB